A center experience with lung transplantation for COVID-19 ARDS

Domingo J. Franco-Palacios\textsuperscript{a,}\textsuperscript{*}, Lisa Allenspach\textsuperscript{a}, Lisa Stagner\textsuperscript{a}, Julio Pinto\textsuperscript{a}, Kaitlin Olexsey\textsuperscript{a}, Eve Sherbin\textsuperscript{b}, William Dillon\textsuperscript{b}, Daniel Sternberg\textsuperscript{c}, Kelly Bryce\textsuperscript{d}, Jane Simanovski\textsuperscript{e}, Dimitrios Apostolou\textsuperscript{e}, Diazo Tanaka\textsuperscript{e}, Hassan Nemeh\textsuperscript{e}, Zhiqiang Wang\textsuperscript{f}, George Alangaden\textsuperscript{b}

\textsuperscript{a} Pulmonary and Critical Care Medicine, Henry Ford Hospital, Detroit, MI, USA
\textsuperscript{b} Infectious Diseases, Henry Ford Hospital, Detroit, MI, USA
\textsuperscript{c} Physical Therapy and Rehabilitation, Henry Ford Hospital, Detroit, MI, USA
\textsuperscript{d} Transplant Institute, Henry Ford Hospital, Detroit, MI, USA
\textsuperscript{e} Thoracic Surgery, Henry Ford Hospital, Detroit, MI, USA
\textsuperscript{f} Pathology Department, Henry Ford Hospital, Detroit, MI, USA

\textbf{A B S T R A C T}

COVID-19 can cause irreversible lung damage from acute respiratory distress syndrome (ARDS), chronic respiratory failure associated with post COVID-19 de novo fibrosis or worsening of an underlying fibrotic lung disease. Pregnant women are at increased risk for invasive mechanical ventilation, extracorporeal membrane oxygenation, and death. The Centers for Disease Control and Prevention reported more than 22,000 hospitalizations and 161 deaths for COVID-19 in pregnant women. Between August 2020 and September 2021, five patients underwent bilateral lung transplant (LT) for COVID-19 ARDS at the Henry Ford Hospital in Detroit, Michigan. De-identified demographics data, clinical characteristics, perioperative challenges, explanted lung pathology, and post-transplant outcomes are described. In post-hospitalization follow-up (median survival 273 days), we see improving endurance and excellent lung function. One patient did not survive to hospital discharge and succumbed to complications 5 months after LT. We report the first cases of bilateral LT in two postpartum women.

1. Introduction

The mortality for COVID-19 ARDS remains high in the range of 20\%–40\% in critically ill patients on mechanical ventilation and extracorporeal membrane oxygenation (ECMO). For patients with refractory ARDS, mortality on veno-venous ECMO (vvECMO) was similar to prepandemic historical data during the first wave \cite{1,2}. Preliminary data showed worse mortality on COVID-19 patients on vvECMO during subsequent waves of the pandemic \cite{3}. Favorable short-term outcomes of lung transplantation (LT) have been reported. The first report in March 2020 described three Chinese patients that underwent successful bilateral LT for COVID-19 ARDS \cite{4}. Others reported on their experience from centers in China, United States, Canada, Italy, Austria, and India \cite{4–9}. The largest single center in the United States described 100\% survival at 30-days post-bilateral LT for COVID-19 ARDS in 3 patients \cite{10}. A recent review of published and unpublished literature described the effectiveness of LT in 21 patients with COVID-19 ARDS \cite{7}. Additional cases of LT have been performed but are unreported. A query of the United Network for Organ Sharing identified COVID-19 as the diagnosis in over 200 LT cases through November 2021 since the United Network for Organ Sharing implementation of COVID-19 as a diagnosis in October 2020 \cite{11}.

\textbf{Abbreviations:} ARDS, acute respiratory distress syndrome; ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IV, intravenous; LT, lung transplantation; mRNA, messenger RNA; vvECMO, veno-venous extracorporeal membrane oxygenation.

\textsuperscript{*} Corresponding author.

\textit{E-mail address:} dfranco1@hfhs.org (D.J. Franco-Palacios).

https://doi.org/10.1016/j.rmcr.2022.101597
Received 16 December 2021; Received in revised form 19 January 2022; Accepted 24 January 2022
Available online 1 February 2022
2213-0071/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics pre and post lung transplant. BLT bilateral lung transplant; IMV invasive mechanical ventilation; ECLS extracorporeal mechanical support with ECMO; CNI calcineurin inhibitor; MMF mycophenolate mofetil; PGD primary graft dysfunction; FEV1 forced expiratory volume, FVC forced vital capacity. Patient 5 only had one spirometry since LT (*).

| Patient | 1 | 2 | 3 | 4 | 5 | Total |
|---------|---|---|---|---|---|-------|
| Age - years | 47 | 37 | 61 | 31 | 35 | Median 37 (IQR 33, 54) |
| Gender | Male | Male | Male | Female | Female | Male (60%) |
| Ethnicity | White | White | Arab American | White | White |
| Body-mass index - kg/m² | 33.5 | 36.9 | 26.92 | 37.5 | 37.5 | Median 36.9 (IQR 30.2, 37.5) |
| ABO group | O+ | A+ | O+ | A+ | A+ | Post-partum, ulcerative colitis |
| Comorbidities | None | Asthma | None | Post-partum, ulcerative colitis |
| COVID-19 characteristics | | | | | | |
| Treatment for COVID-19 | | | | | | |
| - Remdesivir | X | X | X | X | X | 100% |
| - Corticosteroids | X | X | X | X | X | 100% |
| - Tocilizumab | X | X | X | X | X | 60% |
| - Convalescent plasma | | | | | | 20% |
| - Monoclonal antibodies | | | | | | 0% |
| - Antibiotics for pre-LT infection | X | X | X | | | 80% |
| COVID-19 complications | | | | | | |
| - Bacterial pneumonia | X | X | X | X | X | 60% |
| - Pneumothorax | X | X | X | X | X | 40% |
| - Acute kidney injury | | | | | | 20% |
| - Venous thromboembolism | | | | | | |
| - Right ventricular dysfunction | | | | | | |
| Indication for transplantation | COVID-19 ARDS | COVID-19 ARDS | COVID-19 ARDS | COVID-19 ARDS | COVID-19 ARDS |
| Time from COVID-19 to transplant - days | 62 | 114 | 59 | 57 | 54 | Median 54 (IQR 55.5, 88) |
| COVID-19 diagnosis to listing | 62 | 106 | 55 | 47 | 40 | Median 55 (IQR 43.5, 84) |
| COVID-19 diagnosis to negative PCR | 42 | 85 | 50 | 33 | 47 | Median 47 (IQR 37.5, 67.5) |
| COVID-19 diagnosis to ICU admission | 11 | 22 | 8 | 10 | 6 | Median 10 (IQR 7, 16.5) |
| COVID-19 diagnosis to IMV | 21 | 16 | 12 | 16 | 4 | Median 16 (IQR 8, 18.5) |
| COVID-19 diagnosis to vvECMO | 47 | 15 | 45 | 32 | 47 | Median 45 (IQR 23.5, 47) |
| Time from IMV to transplant - days | 40 | 100 | 47 | 30 | 50 | Median 47 (IQR 35.75, 47) |
| Time on ECLS to transplant - days | 15 | 99 | 14 | 25 | 7 | Median 32 (IQR 10.5, 62) |
| Time on wait list - days | 4 | 37 | 4 | 10 | 5 | Median 5 (IQR 4, 23.5) |
| ECLS VV ECMO (single site, dual lumen cannula) | X | X | X | X | X |
| Transplantation characteristics | | | | | | |
| CMV serostatus | D+/R+ | D+/R+ | D+/R+ | D+/R- | D+/R- |
| Tracheostomy at time of transplant | Yes | Yes | Yes | Yes | Yes | 100% |
| Type of transplantation | BLT | BLT | BLT | BLT | BLT |
| Clamshell incision | X | X | X | X | X | 100% |
| VAV ECMO perioperative | | | | | | 40% |
| Total ischemic time - hours | 6.2 | 7.0 | 4.7 | 4.6 | 5.9 | Median 5.68 (IQR 4.65, 6.6) |
| Post-transplantation characteristics | | | | | | |
| Prolonged ECMO support | | | | | | 0% |
| Grade of PGD (0,1, 2, 3, UG) | 3 | 3 | 3 | 0 | 0 | |
| Duration of MV - days | 6 | 161 | 15 | 17 | 49 | Median 17 (IQR 10.5, 105) |
| ICU LOS post LT - days | 32 | 161 | 21 | 26 | 52 | Median 32 (IQR 23.5, 106.5) |
| Total LOS post LT - days | 56 | 161 | 36 | 26 | 67 | |

(continued on next page)
Most of the publications have included male patients, below 60 years of age, and report an early survival rate of 95%. None have included pregnant women with COVID-19 ARDS. Compared to the general population, pregnant women with COVID-19 are at increased risk of severe disease including pre-eclampsia, venous thromboembolism, need for intensive care unit (ICU) care and mechanical ventilation [12–14].

We describe the clinical characteristics and outcomes of the first 5 patients that underwent LT at our center for COVID-19 ARDS, including 2 pregnant women who received transplants in the immediate postpartum period.

2. Materials and methods

The Henry Ford Health System Institutional Review Board approved this case series as minimal-risk research using data collected for routine clinical practice (#14953). Requirement to obtain informed consent for the analysis of consecutive cases was waived by the institutional review board.

SARS-CoV-2 infection was confirmed by nasopharyngeal real-time polymerase chain reaction (PCR) and computed tomography scan of the chest showed changes typical of COVID-19 pneumonia in all cases. Patients with respiratory failure on mechanical support were considered for LT if no evidence of improvement at least 28 days from onset of COVID-19 pneumonia and 2 negative PCR tests for SARS-CoV-2 including one sample from the lower respiratory tract. Patients were evaluated by a multidisciplinary transplant team for determination of non-recovery of lung function and eligibility for transplantation as per expert opinion and endorsed by the International Society for Heart and Lung transplantation criteria [15,16].

Retrospective review of electronic medical records with analysis of demographics, baseline comorbidities, COVID-19 related data, pre- and post-transplant related characteristics and outcomes. We included all patients transplanted for COVID-19 ARDS from January 2021 to September 2021. Only bilateral orthotopic LT was performed.

3. Results

Three males and 2 postpartum females with single organ failure underwent bilateral LT. Median age was 37 years. Clinical characteristics are summarized in Table 1. All patients received systemic corticosteroids (dexamethasone or methylprednisolone), and intravenous (IV) remdesivir for COVID-19 pneumonia. Three were transfers from other facilities for LT evaluation. All were intubated prior to transfer and only one was already on vvECMO at the time of transfer. The remaining two were placed on vvECMO shortly after arrival to our hospital.

Standard ICU management for ARDS included lung protective ventilation, paralytics, systemic corticosteroids, and prone positioning in all cases. Antibiotic therapy, tocilizumab and therapeutic anticoagulation were also used in some patients. Eventually, all patients required ECMO for refractory severe hypoxic respiratory failure.

Poor lung mechanics on invasive mechanical ventilation with radiographic evidence of ground-glass opacities, airspace consolidation and lung fibrosis: pneumatocele, subpleural reticulations and traction bronchiectasis were seen in all patients. Ventilator-associated pneumonia with an identifiable organism by standard lower respiratory culture was diagnosed in 2 patients. vvECMO was instituted with the goal of bridging to transplant in 3 cases, whereas in 2 patients ECMO was used as bridge to recovery but due to dependence on mechanical support without evidence of lung recovery, LT was performed with ECMO as a bridge. Tracheostomy was placed in all patients. Median time to LT from COVID-19 diagnosis was 59 days (interquartile range [IQR]: 54–62 days). Mechanical ventilation median duration was 47 days and median ECMO duration was 32 days (range 7–99 days). Attempts to wean sedation was associated to worsening respiratory status with frequent ventilator dyssynchrony, worsening hypoxia and hemodynamic instability. Median time on the wait list was 5 days (IQR: 4–23.5 days). A substitute decision-maker consented for LT in most cases. Rehabilitation potential and strong social support were absolute inclusion criteria. Postoperative ECMO decannulation was possible in all cases. Donated grafts were from deceased brain death donors and negative for SARS-CoV-2.

Following our perioperative immunosuppression strategy, all but 1 patient received induction immunosuppression with 1 g of

| Patient | 1 | 2 | 3 | 4 | 5 | Total |
|---------|---|---|---|---|---|-------|
| Length of follow up post-discharge - days | 188 | 266 | 331 | 98 | Median 227 (IQR 143, 298) |
| Current status | Alive | Alive | Alive | Alive | Median 273 (IQR 204, 329) |
| Days alive post LT | 244 | 302 | 357 | 165 |
| Lung function (last value) | | | | | |
| FVC L (% pred) | 4.13 (99%) | 3.95 (97%) | 3.25 (95%) | 2.23 (54%)* |
| FEV1 L (% pred) | 3.22 (98%) | 3.19 (104%) | 2.43 (84%) | 2.05 (61%)* |

Most of the publications have included male patients, below 60 years of age, and report an early survival rate of 95%. None have included pregnant women with COVID-19 ARDS. Compared to the general population, pregnant women with COVID-19 are at increased risk of severe disease including pre-eclampsia, venous thromboembolism, need for intensive care unit (ICU) care and mechanical ventilation [12–14].

We describe the clinical characteristics and outcomes of the first 5 patients that underwent LT at our center for COVID-19 ARDS, including 2 pregnant women who received transplants in the immediate postpartum period.

2. Materials and methods

The Henry Ford Health System Institutional Review Board approved this case series as minimal-risk research using data collected for routine clinical practice (#14953). Requirement to obtain informed consent for the analysis of consecutive cases was waived by the institutional review board.

SARS-CoV-2 infection was confirmed by nasopharyngeal real-time polymerase chain reaction (PCR) and computed tomography scan of the chest showed changes typical of COVID-19 pneumonia in all cases. Patients with respiratory failure on mechanical support were considered for LT if no evidence of improvement at least 28 days from onset of COVID-19 pneumonia and 2 negative PCR tests for SARS-CoV-2 including one sample from the lower respiratory tract. Patients were evaluated by a multidisciplinary transplant team for determination of non-recovery of lung function and eligibility for transplantation as per expert opinion and endorsed by the International Society for Heart and Lung transplantation criteria [15,16].

Retrospective review of electronic medical records with analysis of demographics, baseline comorbidities, COVID-19 related data, pre- and post-transplant related characteristics and outcomes. We included all patients transplanted for COVID-19 ARDS from January 2021 to September 2021. Only bilateral orthotopic LT was performed.

3. Results

Three males and 2 postpartum females with single organ failure underwent bilateral LT. Median age was 37 years. Clinical characteristics are summarized in Table 1. All patients received systemic corticosteroids (dexamethasone or methylprednisolone), and intravenous (IV) remdesivir for COVID-19 pneumonia. Three were transfers from other facilities for LT evaluation. All were intubated prior to transfer and only one was already on vvECMO at the time of transfer. The remaining two were placed on vvECMO shortly after arrival to our hospital.

Standard ICU management for ARDS included lung protective ventilation, paralytics, systemic corticosteroids, and prone positioning in all cases. Antibiotic therapy, tocilizumab and therapeutic anticoagulation were also used in some patients. Eventually, all patients required ECMO for refractory severe hypoxic respiratory failure.

Poor lung mechanics on invasive mechanical ventilation with radiographic evidence of ground-glass opacities, airspace consolidation and lung fibrosis: pneumatocele, subpleural reticulations and traction bronchiectasis were seen in all patients. Ventilator-associated pneumonia with an identifiable organism by standard lower respiratory culture was diagnosed in 2 patients. vvECMO was instituted with the goal of bridging to transplant in 3 cases, whereas in 2 patients ECMO was used as bridge to recovery but due to dependence on mechanical support without evidence of lung recovery, LT was performed with ECMO as a bridge. Tracheostomy was placed in all patients. Median time to LT from COVID-19 diagnosis was 59 days (interquartile range [IQR]: 54–62 days). Mechanical ventilation median duration was 47 days and median ECMO duration was 32 days (range 7–99 days). Attempts to wean sedation was associated to worsening respiratory status with frequent ventilator dyssynchrony, worsening hypoxia and hemodynamic instability. Median time on the wait list was 5 days (IQR: 4–23.5 days). A substitute decision-maker consented for LT in most cases. Rehabilitation potential and strong social support were absolute inclusion criteria. Postoperative ECMO decannulation was possible in all cases. Donated grafts were from deceased brain death donors and negative for SARS-CoV-2.

Following our perioperative immunosuppression strategy, all but 1 patient received induction immunosuppression with 1 g of

| Patient | 1 | 2 | 3 | 4 | 5 | Total |
|---------|---|---|---|---|---|-------|
| Anti-rejection regimen | | | | | | Median 56 (IQR 31, 114) |
| Induction | X | X | X | X | 80% |
| Calcineurin inhibitor | X | X | X | X | 100% |
| Mycophenolate mofetil | X | X | X | X | 80% |
| Corticosteroids | X | X | X | X | 100% |
| Length of follow up post-discharge - days | 188 | 266 | 331 | 98 | Median 227 (IQR 143, 298) |
| Current status | Alive | Alive | Alive | Alive | Median 273 (IQR 204, 329) |
| Days alive post LT | 244 | 302 | 357 | 165 |
| Lung function (last value) | | | | | |
| FVC L (% pred) | 4.13 (99%) | 3.95 (97%) | 3.25 (95%) | 2.23 (54%)* |
| FEV1 L (% pred) | 3.22 (98%) | 3.19 (104%) | 2.43 (84%) | 2.05 (61%)* |
methylprednisolone, 750 mg of mycophenolate and 20 mg IV of basiliximab (dose repeated on day 4 post-LT). Maintenance immuno-
suppression with addition of tacrolimus on post-LT day 4 and prophylaxis is standard for our center. Patient 2 in Table 1 did not receive basiliximab and mycophenolate induction immunosuppression as he had history of Enterococcus and Escherichia coli bacteremia during his ICU stay prior to LT, and his donor lungs grew Burkholderia gladioli and Candida glabrata from bronchoalveolar lavage.

Two of our patients were pregnant women with COVID-19 infection. Our first case was a 31-year-old woman, gravida 1, para 0, with history of obesity and ulcerative colitis. She was hospitalized with COVID-19 and severe pre-eclampsia. Seven days later, at 36 weeks gestation she vaginally delivered a healthy female infant. She was treated with dexamethasone 6 mg daily, IV remdesivir, IV unfractionated heparin, vitamin C, zinc and received antibiotics for endometritis. Due to disease progression, she was intubated and put on mechanical ventilation on day 16 after confirmation of COVID-19. Five days later vvECMO was initiated for refractory severe hypoxic respiratory failure secondary to COVID-19 ARDS. She had a right spontaneous pneumothorax that was drained with a small-bore chest tube. Due to hemodynamic instability, VAV ECMO was necessary 4 days before listing. After approximately 5 weeks on ECMO and 10 days after listing, she received a bilateral LT in January 2021. The patient was unvaccinated for COVID-19.

Another 35-year-old woman, gravida 1, para 0, with history of asthma, obesity and nephrolithiasis was hospitalized for COVID-19 pneumonia. She was treated with methylprednisolone, IV remdesivir and IV tocilizumab but had progressive respiratory failure and was intubated on hospital day 4. Due to non-reassuring fetal status in the setting of COVID-19 ARDS, she underwent cesarean section, giving birth to a healthy female infant at 35 weeks of gestation, four days after COVID-19 diagnosis. She developed pneumonia due to Serratia species and pulmonary embolism treated with IV cefepime and full-dose anticoagulation, respectively. She required placement of a chest tube for left-sided pneumothorax. Despite treatment, she failed to show recoverable lung function. She was cannulated for vvECMO as a bridge to LT 43 days after invasive mechanical ventilation. Seven days after she was listed, she received a bilateral LT from a deceased donor. The patient was unvaccinated for COVID-19.

Both pregnant patients were obese, and in their thirties, which have been described as risk factors for poor outcomes. Pre-eclampsia in the first patient and pulmonary embolism in the second have been described as complications of COVID-19 in pregnancy and are associated to increase mortality. Both patients also developed pneumothoraces before bilateral LT.

All 5 patients had radiologic and pathologic confirmation of end-stage irreversible COVID-19 pneumonia. Explanted pathology in all cases showed interstitial fibrosis, diffuse alveolar damage, diffuse hemorrhage and one case of fibrosing non-specific interstitial pneumonia (Fig. 1). Pulmonary hypertension was seen in 3 cases.

One male patient did not survive. He developed primary graft dysfunction 3 (PGD) as well as other complications: hemorrhagic pancreatitis, deep vein thrombosis, right main bronchus anastomosis dehiscence, pseudoaneurysm of left colic artery and empyema. He eventually died from septic shock secondary to Gram negative bacteremia and candidemia 5 months after bilateral LT and 6 months after confirmed COVID-19 pneumonia.

Despite high doses of narcotics/sedations pre-transplant, all survivors were free of narcotics at time of hospital discharge with no signs of narcotic dependence. Four patients have post-hospitalization follow-up demonstrating excellent lung function in the three
patients with longer follow-up. Median follow-up post-hospitalization is 227 days (range, 98–331 days). All 4 have stable radiographic findings without identification of clinically significant acute allograft rejection (acute cellular rejection A2 or higher, or antibody mediated rejection) in surveillance bronchoscopies.

4. Discussion

We describe the characteristics and outcomes of the first 5 patients that underwent LT at our center for COVID-19 ARDS, including 2 pregnant women in the immediate postpartum period.

For COVID-19 ARDS, general guidelines recommend careful selection of patients for LT in cases of irreversible, end-stage COVID-19 lung disease based on clinical grounds and evidence of extensive fibrotic lung disease as demonstrated on computed tomography [15]. Undetectable presence of SARS-CoV-2 by PCR in 2 respiratory samples obtained 24 hours apart and including one from alveolar lavage or lower respiratory tract is necessary [16]. In most reported cases, transplant has been performed in individuals under 65 years of age with single organ dysfunction (lungs) and after allowing enough time for lung recovery [10,15]. Most cases have been performed off ECMO (Table 2) [4–6,8,9]. Rehabilitation potential prior to acute illness must be present. Other absolute contraindications for LT in the general population of end-stage lung diseases must not be present [17,18]. Most LTs for COVID-19 ARDS have been bilateral due to the frequent presence of pulmonary hypertension and superimposed bacterial pneumonias. LT in this setting is recommended to be performed in centers with experience in high-risk transplantation (including experience on ECMO) due to the challenging perioperative and postoperative care with expected prolonged ICU stay [6]. All of our 5 cases of COVID-19 ARDS met the general guidelines described above for LT.

The characteristics of our 5 cases are comparable to that reported so far, with ages ranging from 31 to 61 years (Table 2). All had single organ (lung) failure, with time from COVID-19 diagnosis of 54–114 days and time on ECMO support of 7–99 days. The period of follow-up is longer in our report, up to 11 months.

### Table 2

Summary of global reports of lung transplantation for COVID-19 respiratory failure (published cases and current study).

| Author          | Country   | No. of Cases | Age (years) | Sex | Type of LT | COVID-19 diagnosis to LT (days) | IMV | ECMO support (days) | Pre-LT ECMO type | Intra-op ECMO | ECLS | ECMO Post-op (days) | Follow-up (months) and outcomes |
|-----------------|-----------|--------------|-------------|-----|------------|---------------------------------|-----|---------------------|-----------------|---------------|------|-------------------|-------------------------------|
| Bharat et al.   | USA/2020  | 3            | 28 F        | M   | BLT        | 40                              | X   | 32                  | VV              |               |      |                   | 17                            |
| Chen JY et al.  | China/2020| 3            | 66 M        | M   | H-L        | 42                              | X   | 15                  | VAV             | VA            | ECMO |                   | X 1.5                         |
| Lang et al.     | Austria/2020| 1            | 44 F        | M   | BLT        | 58                              | X   | 35                  | VV              |               |      |                   | X 3                           |
| Han W et al.    | China/2020 | 2            | 66 F        | M   | BLT        | 30                              | X   |                      |                 |               |      |                   | 5                            |
| Maniar et al.   | USA/2021  | 1            | 51 M        | F   | BLT        | 84                              | X   | 82                  | VV              |               |      |                   | X 3                           |
| Gok et al.      | USA/2021  | 2            | 69 M        | M   | BLT        | 57                              |     |                      |                 |               |      |                   | 5                            |
| Yeung et al.    | Canada/2021| 3            | 60 M        | M   | BLT        | 59                              | X   | 17                  | VV              |               |      |                   | 4                            |
| Hawkins et al.  | USA/2021  | 1            | 57 M        | M   | BLT        | 50                              | X   | 14                  | VV              |               |      | CPB               | 4                            |

Note: LT, lung transplantation; BLT, bilateral lung transplantation; IMV, invasive mechanical ventilation; ECMO, extracorporeal oxygenation; ECLS, extracorporeal life support; CPB cardiopulmonary bypass

5
Our report is the first to describe successful LT for COVID-19 ARDS in post-partum women. In both cases the infants were born healthy. Women especially those infected with the SARS-CoV-2 delta variant during pregnancy are likely to have worse outcomes due to the increased risk of severe COVID-19 [12–14]. There is also an increased risk for adverse pregnancy and neonatal outcomes, including preterm birth and admission of their neonate(s) to an ICU [13,19,20]. At the time of their COVID diagnosis, safety of messenger RNA (mRNA) vaccines was not well established and like in our 2 cases, most pregnant women in the United States at that time were not vaccinated. Current safety data of mRNA vaccines in pregnant women, and on women planning to get pregnant, support the Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists recommendation for COVID-19 vaccination in this patient population [21,22].

LT for COVID-19 presents additional challenges. Participation of the patient on decision making, comprehensive psychosocial evaluation, pre-transplant education and rehabilitation is often not possible due to the severity of their illness and limitations of being in infection isolation. Sedated COVID-19 ARDS patients, who were not able to engage in decision making process, wake with shock, fear, disbelief of what they had undergone. Waking up after unknowingly undergone lung transplantation can be traumatic for patients and has resulted in a variety of concerning psychosocial outcomes. We have found a spectrum of psychological symptoms and diagnoses, ranging from acceptance and gratitude to severe depression, anxiety, and anger. Patients have reported symptoms consistent with an acute stress reaction (which can develop into PTSD over time). The seemingly insurmountable challenge of accepting what had happened to them and poor coping can significantly negatively impact the patient’s ability to appropriately engage in their care, leading to a myriad of additional problems and complications.

Regarding medical decision making, ethical principles of beneficence, non-maleficence, and justice were certainly taken into consideration; however, with the patient unable to engage in decision making, their freedom to choose (autonomy) has been taken away [23]. It can be agreed that all involved proceeded with what they felt was in the best interest of the patient. However, the inability to demonstrate one’s autonomy in such a life changing decision can also impact the patient’s ability to cope with and accept transplantation and its associated lifestyle changes. Given these unique circumstances, close follow up with a psychologist or other mental health provider is recommended to support patients as they adjust to post-transplant life.

The diagnosis of COVID made a consistent and typical rehabilitation course not possible due to the innate medical complexities of the disease (intubation, sedation, paralytics, prone positioning, and high doses of inotropic support) [24]. Physical and occupational therapy in our patients were inconsistent and many times limited to bed exercises due the patients’ frequently changing medical status, and the various tests and procedures being performed. This was further restricted by pain, edema, and endurance. ICU myopathy, deconditioning, and delirium were common occurrences in these patients.

4.1. Limitations

This is a retrospective single-center cohort study of 5 patients. The literature reviewed only peer-reviewed publications of case reports/series without systematic data collection and insufficient information on post-LT outcomes. This short follow-up does not provide an answer regarding long-term outcomes.

5. Conclusion

In the United States, most LT for COVID-19 is for irreversible severe COVID-19 ARDS. LT for ARDS is reserved for the minority of carefully selected patients dependent on extracorporeal life support. As we and others have reported, short-term survival appears to be good; however, long-term outcome data is yet to be described. It will be important for centers without transplant programs to establish a close line of communication with transplant centers and for transplant centers to streamline the process to allow transferring of a very ill patient that on initial assessment could be considered for this lifesaving procedure. Acknowledging the commonly present complications and the shortcomings of an incomplete evaluation, a very careful selection of patients can save some lives.

Declaration of competing interest

The author(s) declare that there is no conflict of interest.

References

[1] R.P. Barbaro, G. MacLaren, P.S. Boonstra, et al., Extracorporeal life support organization. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the extracorporeal life support organization registry, Lancet 396 (10257) (2020) 1071–1078.
[2] M. Schmidt, D. Hajage, G. Lebreton, et al., Groupe de Recherche Clinique en REanimation et Soins intensifs du Patient en Insuffisance Respiratoire aiguE (GRC-RESPIRE) Sorbonne Université; Paris-Sorbonne ECMO-COVID investigators. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study, Lancet Respir. Med. 8 (11) (2020) 1121–1131.
[3] J. Badulak, M.V. Antonini, C.M. Stead, et al., ELSO COVID-19 Working Group Members, Extracorporeal membrane oxygenation for COVID-19: updated 2021 guidelines from the extracorporeal life support organization, Am. Soc. Artif. Intern. Organs J. 67 (5) (2021) 485–495.
[4] J.Y. Chen, K. Qiao, F. Liu, et al., Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis, Chin. Med. J. (Engl). 133 (12) (2020) 1390–1396.
[5] W. Han, M. Zhu, J. Chen, et al., Lung transplantation for elderly patients with end-stage COVID-19 pneumonia, Ann. Surg. 272 (1) (2020) e33–e34.
[6] A. Bharat, T.N. Machuca, M. Querrey, et al., Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries, Lancet Respir. Med. 9 (5) (2021) 487–497.
[7] R.B. Hawkins, J.J. Mehaffey, E.J. Charles, H.C. Mannem, M. Roesser, Lung transplantation for severe post-coronavirus disease 2019 respiratory failure, Transplantation 105 (6) (2021) 1381–1387.
[8] J.C. Yeung, M. Cypel, C. Chaparro, S. Keshavjee, Lung transplantation for acute COVID-19: the Toronto lung transplant program experience, CMAJ (Can. Med. Assoc. J.) 193 (38) (2021) E1494–E1497.
[9] C. Lang, P. Jaksch, M.A. Hoda, et al., Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient, Lancet Respir. Med. 8 (10) (2020) 1057–1060.

[10] A. Bharat, M. Querrey, N.S. Markov, et al., Lung transplantation for patients with severe COVID-19, Sci. Transl. Med. 12 (574) (2020), eabe4282.

[11] C.S. King, H. Mannem, J. Kukreja, et al., Lung transplantation of COVID-19 patients: how do I do it, Chest (2021), https://doi.org/10.1016/j.chest.2021.08.041.

[12] E.H. Adhikari, J.A. Soltelle, D.D. McIntire, C.Y. Spong, Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge, Am. J. Obstet. Gynecol. (2021), https://doi.org/10.1016/j.ajog.2021.09.008.

[13] J. Allety, E. Stallings, M. Bonet, et al., For PregCOVID-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis, BMJ 370 (2020) m3320.

[14] J. Villar, S. Ariff, R.B. Gunier, et al., Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study, JAMA Pediatr. 175 (8) (2021) 817–826.

[15] M. Cypel, S. Keshavjee, When to consider lung transplantation for COVID-19, Lancet Respir. Med. 8 (10) (2020) 944–946.

[16] International Society of Heart and Lung Transplantation, Deceased donor and recipient selection for cardiothoracic transplantation during the COVID-19 pandemic: recommendations from the ISHLT COVID-19 Task Force. https://ishlt.org/ishlt/media/documents/COVID-19_GuidanceDocument_Deceased-donor-and-recipient-selection-for-cardiothoracic-transplantation.pdf, 2021. (Accessed 19 November 2021).

[17] D. Weill, C. Benden, P.A. Corris, et al., A consensus document for the selection of lung transplant candidates: 2014–an update from the pulmonary transplantation council of the international society for heart and lung transplantation, J. Heart Lung Transplant. 34 (1) (2015) 1–15.

[18] L.E. Leard, A.M. Holm, M. Valapour, et al., Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation, J. Heart Lung Transplant. 40 (11) (2021) 1349–1379.

[19] J.Y. Ko, C.L. DeSisto, R.M. Simeone, et al., Adverse pregnancy outcomes, maternal complications, and severe illness among US delivery hospitalizations with and without a Coronavirus Disease 2019 (COVID-19) diagnosis, Clin. Infect. Dis. 73 (Suppl 1) (2021) S24–S31.

[20] K.S. Jering, B.L. Claggett, J.W. Cunningham, et al., Clinical characteristics and outcomes of hospitalized women giving birth with and without COVID-19, JAMA Intern. Med. 181 (3) (2021) 714–717.

[21] Health Alert Network, Centers for Disease Control and Prevention, COVID-19 vaccination for pregnant people to prevent serious illness, deaths, and adverse pregnancy outcomes from COVID-19, https://emergency.cdc.gov/han/2021/han00453.asp, 2021. (Accessed 19 November 2021), 29.

[22] American College of Obstetricians and Gynecologists, COVID-19 vaccination considerations for obstetric-gynecologic Care, Updated November 3, 2021, https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care, 2020. (Accessed 19 November 2021).

[23] A.M. Holm, M.R. Mehra, A. Courtwright, et al., Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement, J. Heart Lung Transplant. 39 (7) (2020) 619–626.

[24] D. Langer, Rehabilitation in patients before and after lung transplantation, Themat. Rev. Ser. 89 (2015) 353–362, https://doi.org/10.1159/00043045.